Q4 2025 Evotec SE Earnings Call Transcript
Key Points
- Evotec SE (EVOTF) achieved significant progress in 2025, delivering over EUR60 million in annualized cost savings and reducing capital expenditure by around 60%, strengthening its financial resilience.
- The company introduced a new strategy in 2025, focusing on scientific leadership, operational excellence, and better monetization, which has already translated into targeted actions.
- Evotec SE (EVOTF) saw robust clinical and scientific advancements in key therapeutic areas, including oncology and neurodegeneration, with several assets advancing to Phase I and II clinical studies.
- The Just - Evotec Biologics segment experienced a breakthrough year, highlighted by a strategic agreement with Sandoz valued at $650 million, and significant progress in global health programs.
- Evotec SE (EVOTF) is implementing the Horizon transformation, expected to deliver structural run rate savings of approximately EUR75 million by the end of 2027, enhancing operational efficiency and competitiveness.
- Despite progress, Evotec SE (EVOTF) faced a challenging market environment in 2025, with a decline in full-year revenues by 1.1% compared to 2024, primarily due to lower revenues in the Discovery and Preclinical Development segment.
- The company experienced unfavorable foreign exchange movements, representing a 2.8% headwind to full-year revenues, driven by the US dollar and British pound.
- Adjusted EBITDA in the Discovery and Preclinical Development segment decreased significantly, highlighting the need for operational transformation to address internal overcapacity and improve profitability.
- The Horizon transformation involves the closure of four sites and a reduction of approximately 800 positions, posing potential risks of customer disruption and talent loss.
- Evotec SE (EVOTF) anticipates a high-single-digit decline in revenues from its partnership with Bristol Myers Squibb in 2026, reflecting a transition into a renewed investment phase.
(audio in progress) Before we begin, a few forward-looking statements. The discussion and responses to your questions on this call reflect management's views as of today, Wednesday, April 8, 2026. During this call, we will make statements and provide responses that state our intentions, beliefs, expectations, or projections regarding the future. These statements constitute forward-looking statements within the meaning of applicable securities laws. They are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied.
Evotec disclaims any intention or obligation to update or revise any forward-looking statements to reflect subsequent events or circumstances. For further information regarding these risks and uncertainties, please refer to our public filings and disclosures. With this, let me hand over the call to Christian.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
